Aviva PLC Y M Abs Therapeutics, Inc. Transaction History

Aviva PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$25.45 - $37.64 $976,032 - $1.44 Million	-38,351 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$29.16 - $51.96 $157,405 - $280,480	5,398 Added 16.38%	38,351 $1.16 Million
Q4 2020 Feb 10, 2021	SELL	$37.86 - $54.26 $1.01 Million - $1.45 Million	-26,714 Reduced 44.77%	32,953 $1.63 Million
Q3 2020 Nov 12, 2020	BUY	$35.13 - $43.62 $332,364 - $412,688	9,461 Added 18.84%	59,667 $2.29 Million
Q2 2020 Aug 13, 2020	SELL	$23.66 - $49.53 $1.95 Million - $4.08 Million	-82,407 Reduced 62.14%	50,206 $2.17 Million
Q1 2020 May 14, 2020	BUY	$14.39 - $35.8 $1.91 Million - $4.75 Million	132,613 New	132,613 $3.46 Million

107

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $259M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.